Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias.

Abstract

To investigate the association between the onset, severity, and type of immune-related adverse events (irAEs) and the efficacy of pembrolizumab in patients with platinum-pretreated advanced urothelial carcinoma (UC), we retrospectively collected clinical datasets of 755 patients and conducted landmark analysis. Patients who survived for fewer than 3 months were excluded from the evaluation to reduce the immortal time bias. In total, 620 patients were evaluated, of whom 220 patients (35.5%) experienced grade≥2 irAEs, including 134 patients with grade 2 irAEs and 86 with grade≥3 irAEs. Propensity score matching extracted 198 patients with and without grade≥2 irAEs. The onset of grade≥2 irAEs was associated with longer median progression-free survival (PFS) (8.3 months vs. 4.5 months, p=0.003) and overall survival (OS) (20.4 months vs. 14.3 months, p=0.031) and a higher objective response rate (ORR) (44.8% vs. 30.2%, p=0.004). Patients with grade 2 irAEs had significantly better oncological outcomes (PFS, OS, and ORR) than grade≤1 and≥3 irAEs. Patients with grade≥3 irAEs had worse outcomes than grade 2 irAEs. Endocrine and skin irAEs were related with better survival outcomes, and the rate of severities was lower in these categories. In conclusion, the occurrence of irAEs, particularly low-grade irAEs, was predictive of pembrolizumab efficacy in patients with platinum-pretreated advanced UC.